Introduction: Pulmonary arterial hypertension
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive disease with poor prognosis. It is generally characterized by constriction of pulmonary arteries and vascular remodeling.
Right ventricular afterload (right ventricular hypertrophy and enlargement) is increased because of elevated pulmonary arterial pressure and pulmonary vascular resistance, which ultimately leads to right cardiac failure and death [1] . Subjective symptoms of PAH include exertional dyspnea, fatigability, palpitations, chest pain, and syncope [2] . Although the underlying mechanisms of PAH are not fully understood, vascular endothelial abnormalities cause an imbalance between vasoconstricting and vasodilating factors. In this situation, vasoconstricting factors exert a greater influence and increase shear stress. It is generally thought that remodeling of the pulmonary arterial media and narrowing of the pulmonary intravascular lumens due to increased cell proliferation are responsible for this imbalance [3] [4] [5] . [6] [7] [8] .
PGI 2 is a metabolite of arachidonic acid and plays an important role in maintaining pulmonary vascular homeostasis. It is produced by endocapillary cells, and acts as a potent vasodilator and inhibits platelet aggregation. Accordingly, the PGI 2 system plays an important role in the inhibition of vascular smooth muscle cell proliferation and helps to protect the vascular endothelium. A small decline in the function of the PGI 2 system leads to an imbalance between vasoconstrictors and vasodilators, and appears to contribute to the development of PAH [9] [10] [11] .
Based on these findings, compounds that target prostacyclin receptors have been developed and are used clinically to treat PAH. One such example is intravenous epoprostenol sodium, a synthetic PGI 2 analog, which is prepared as a formulation containing glycine and mannitol as excipients (epoprostenol GM, GlaxoSmithKline, London, UK). Continuous intravenous therapy with epoprostenol GM was reported to improve pulmonary hemodynamic factors, exercise tolerance, and the prognosis of PAH [12] . However, one limitation of this formulation is that the prepared solution is thermally unstable, and needs to be administered within 8 h at room temperature (1-30°C) or within 24 h if cooled to 2-8°C using frozen gel packs. Consequently, the medication cassette containing the solution has to be maintained at 2-8°C using a frozen gel pack for the entire 24-h infusion period [13] .
To overcome this limitation, another formulation of epoprostenol sodium, containing arginine and sucrose as excipients (Actelion Pharmaceuticals Japan Ltd., Tokyo, Japan; hereafter, epoprostenol AS), was developed to improve the convenience of using epoprostenol to treat PAH as the new formulation is stable for 24 h at room temperature [14] .
To date, however, few studies have examined the safety, potential effects on hemodynamic factors, or treatment satisfaction associated with switching formulations of epoprostenol in patients with PAH [15] . Therefore, the authors performed a 12-week, open-label, Phase 3b study to examine the safety, efficacy, and treatment satisfaction of switching from epoprostenol GM to epoprostenol AS in Japanese patients with PAH. The authors hypothesized that switching from epoprostenol GM to epoprostenol AS would improve treatment satisfaction without increasing the incidence of adverse events or causing deteriorations in pulmonary hemodynamic factors.
METHODS

Ethics
All procedures followed were in accordance with the ethical standards of the responsible 
Outcome Measures
Safety/Tolerability
The safety/tolerability endpoints were adverse events occurring during the 12-week treatment phase, together with changes from baseline to week 12 for vital signs (blood pressure and heart rate on the same arm in sitting or supine position), body weight, and abnormal changes from baseline to week 12 for clinical laboratory tests (general biochemistry tests, including thyroid function test and hematology test). Vital signs and body weight were assessed at each visit and clinical laboratory tests were performed at baseline and week 12 (only thyroid function was assessed every month).
Adverse events reported during the 12-week evaluation period were coded according to system organ class and terms using the Medical Dictionary for Regulatory Activities/ Japanese version. The causality of adverse events in relation to the trial drug was judged by the investigators.
Efficacy Endpoints
The efficacy endpoints were changes in Pulmonary hemodynamics were measured by right heart catheterization, which was performed according to standard local procedures through the internal jugular, subclavian, or femoral vein by a balloon catheter placed into either the right or left pulmonary artery in a sterilized cardiac catheterization laboratory. Cardiac Output (CO) was measured using Fick's method [18] .
Treatment Satisfaction
The abbreviated nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), employed for the quality of life assessment, is a validated questionnaire that permits comparisons of patients' treatment satisfaction across medication types and patient conditions [19] . The changes from baseline to week 12 in treatment satisfaction were assessed using the TSQM-9. This questionnaire includes three items for each of three domains: effectiveness, convenience, and global satisfaction. The scores for each domain range from 0 to 100, where higher scores indicate higher satisfaction on that domain.
Statistical Analysis
This study was an exploratory study. No hypothesis was set and no power considerations were made for this study.
Patients who received at least one dose of the study drug were included in the all-treated set for analyses. Patients who had assessable data at baseline and week 12 were included in the analysis of pulmonary hemodynamics. All statistical analyses were considered to be exploratory and the significance level was set at 5% (two-sided). The efficacy variables were summarized descriptively by calculating the mean, standard deviation, standard error, median, 25th and 75th percentiles, minimum and maximum. Changes from baseline were examined using the Wilcoxon signed rank sum test. All analyses were performed using SAS (Version 9.2; SAS Inc., Cary, North Carolina, USA).
RESULTS
Patients
The study was conducted at two Japanese study sites, and started in October 2011. Eight Japanese patients (one male, seven females)
with PAH were treated with the study drug and completed the 12-week evaluation period by October 2012. The characteristics of the patients are summarized in Table 1 and  Supplemental Table 1 . The mean (range) age 
Safety
Adverse events reported during the 12-week evaluation period are summarized in Table 2 according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities/Japanese version. Seven out of eight patients (87.5%) experienced a total of 18 adverse events. Three patients (37.5%) experienced a total of four adverse events that were considered related to the study drug. Two patients (25.0%) experienced serious adverse events: moderate pneumonia and mild device dislocation in one patient each, both of which were not considered related to the study drug. There were no deaths or adverse events leading to treatment discontinuation during the study. Seven out of eight patients (87.5%) experienced mild adverse events and three (37.5%) experienced moderate adverse events; there were no severe adverse events.
The most frequent event was nausea, which was reported by two patients. The other adverse events occurred in one patient only. There were no clinically significant changes from baseline to week 12 in blood pressure, heart rate, body weight, or clinical laboratory tests.
Efficacy Table 3 shows the hemodynamic factors measured within 60 min before (i.e., baseline) and 60 min after the first dose of epoprostenol, as well as the changes between these two times.
As shown in Table 3 , there were no marked changes in pulmonary hemodynamic parameters from 60 min before to 60 min after the first dose of epoprostenol AS. Wilcoxon signed rank sum tests revealed no significant differences at the 5% level for the changes from baseline. Table 4 presents the hemodynamic factors measured at baseline and at week 12, together with their changes between these times. As shown in Table 4 , there were no remarkable changes in pulmonary hemodynamic factors from baseline to week 12. Additionally, Wilcoxon signed rank sum tests revealed no significant differences at the 5% level for the changes from baseline. The WHO functional class was unchanged from baseline to week 12, as one was categorized as Class I, five as Class II, and two as Class III (Table 5 ). The mean (range) NT-proBNP concentration was 139 (57-240) pg/mL at baseline and 106 (41-243) pg/mL at week 12.
The mean (range) change from baseline to week 12 was --43.3 (-196 to 43) pg/mL, which was not clinically significant (Wilcoxon signed rank sum test: P = 0.5781) (Fig. 1) . Table 6 shows the scores for all three domains of the TSQM-9 recorded at baseline and week 12, together with the changes from baseline to week 12. As shown in this table, there were improvements in all three domains during the 
Treatment Satisfaction
DISCUSSION
The results of this study demonstrate that patients with PAH can be switched from epoprostenol GM to a new formulation of epoprostenol sodium, epoprostenol AS, with no apparent safety concerns or deteriorations in pulmonary hemodynamic factors. Switching from epoprostenol GM to epoprostenol AS was also associated with an improvement in convenience across three treatment satisfaction domains.
The new formulation of epoprostenol is stable for 24 h at room temperature (1-30°C) after preparation/dilution in saline, and the prepared solution does not require cooling with a frozen gel pack, which is expected to improve the quality of life of patients, particularly in terms of their daily activities. This expectation is supported by the results of the treatment satisfaction questionnaire, which showed an improvement in convenience. Therefore, patients with PAH treated with conventional formulations of epoprostenol sodium could be switched to epoprostenol AS, a stable formulation at room temperature, and may enhance their quality of life through improvements in treatment convenience. The outdoor air temperature during the summer in many regions of Japan often exceeds 30°C, and the temperature around the medication cassette of the diluted solution could be even higher [20] . As part of the riskmanagement strategy in this study, patients were instructed to use a frozen gel pack during the summer, especially when the environmental temperature exceeded room temperature. In this study, two out of eight patients used a frozen gel pack during the treatment period, but neither of these patients experienced any changes in their overall AE adverse event, pts patients Table 3 Changes in hemodynamic parameters from baseline to within 60 min after switching epoprostenol formulations 
CONCLUSION
In conclusion, the present study showed that switching to a new formulation of epoprostenol was associated with an improvement in convenience in relation to treatment satisfaction, without unexpected adverse 
FC functional class, WHO World Health Organization 
